Cancer Research The Future of Cancer Research: Science and Patient Impact  Translational Medicine Conference in Israel
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 48, 2929-2932, May 15, 1988]
© 1988 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pippard, E. C.
Right arrow Articles by Bridges, B. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pippard, E. C.
Right arrow Articles by Bridges, B. A.

Cancer in Homozygotes and Heterozygotes of Ataxia-Telangiectasia and Xeroderma Pigmentosum in Britain

E. Clare Pippard, Andrew J. Hall, David J. P. Barker and Bryn A. Bridges1

The MRC Environmental Epidemiology Unit, University of Southampton, Southampton General Hospital, Southampton [E. C. P., A. J. H., J. P. B.]; and the MRC Cell Mutation Unit, University of Sussex, Falmer, Brighton [B. A. B.], England

We have documented mortality and cancer incidence in the families of 67 patients with ataxia-telangiectasia and 48 patients with xeroderma pigmentosum resident in Britain. For both diseases, parents of patients are obligate heterozygotes and grandparents have a probability of heterozygosity of 0.5.

Fourteen ataxia-telangiectasia patients had died by June 30, 1986. This was a significant excess (14 deaths observed, 1.65 expected). Only one death was from a malignancy (non-Hodgkin's lymphoma). Three parents of ataxia-telangiectasia patients had died, all from cancer. The excess from breast cancer (two deaths observed, 0.17 expected) was statistically significant, p < 0.05. However, no excess mortality from malignant neoplasms was found in the grandparents.

Five xeroderma pigmentosum patients had died, none from internal malignancies. No excess mortality from malignant neoplasms was recorded in either their parents or grandparents.

1 To whom requests for reprints should be addressed, at MRC Cell Mutation Unit, University of Sussex, Falmer, Brighton BN1 9RR, England.

Received 8/12/87. Revised 1/19/88. Accepted 2/ 8/88.




This article has been cited by other articles:


Home page
Cancer Res.Home page
P. Concannon, R. W. Haile, A.-L. Borresen-Dale, B. S. Rosenstein, R. A. Gatti, S. N. Teraoka, A. T. Diep, L. Jansen, D. P. Atencio, B. Langholz, et al.
Variants in the ATM Gene Associated with a Reduced Risk of Contralateral Breast Cancer
Cancer Res., August 15, 2008; 68(16): 6486 - 6491.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
K. Offit, S. Gilad, S. Paglin, P. Kolachana, L. C. Roisman, K. Nafa, V. Yeugelewitz, M. Gonzales, M. Robson, D. McDermott, et al.
Rare Variants of ATM and Risk for Hodgkin's Disease and Radiation-associated Breast Cancers
Clin. Cancer Res., December 1, 2002; 8(12): 3813 - 3819.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
D. Tang, D. Wu, A. Hirao, J. M. Lahti, L. Liu, B. Mazza, V. J. Kidd, T. W. Mak, and A. J. Ingram
ERK Activation Mediates Cell Cycle Arrest and Apoptosis after DNA Damage Independently of p53
J. Biol. Chem., April 5, 2002; 277(15): 12710 - 12717.
[Abstract] [Full Text] [PDF]


Home page
J. Med. Genet.Home page
M M de Jong, I M Nolte, G J te Meerman, W T A van der Graaf, J C Oosterwijk, J H Kleibeuker, M Schaapveld, and E G E de Vries
Genes other than BRCA1 and BRCA2 involved in breast cancer susceptibility
J. Med. Genet., April 1, 2002; 39(4): 225 - 242.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
T. Dork, R. Bendix, M. Bremer, D. Rades, K. Klopper, M. Nicke, B. Skawran, A. Hector, P. Yamini, D. Steinmann, et al.
Spectrum of ATM Gene Mutations in a Hospital-based Series of Unselected Breast Cancer Patients
Cancer Res., October 1, 2001; 61(20): 7608 - 7615.
[Abstract] [Full Text] [PDF]


Home page
JNCI J Natl Cancer InstHome page
J. H. Olsen, J. M. Hahnemann, A.-L. Borresen-Dale, K. Brondum-Nielsen, L. Hammarstrom, R. Kleinerman, H. Kaariainen, T. Lonnqvist, R. Sankila, N. Seersholm, et al.
Cancer in Patients With Ataxia-Telangiectasia and in Their Relatives in the Nordic Countries
J Natl Cancer Inst, January 17, 2001; 93(2): 121 - 127.
[Abstract] [Full Text] [PDF]


Home page
ANN INTERN MEDHome page
Y. Su and M. Swift
Mortality Rates among Carriers of Ataxia-Telangiectasia Mutant Alleles
Ann Intern Med, November 21, 2000; 133(10): 770 - 778.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
K. E. Nichols, S. Levitz, K. E. Shannon, D. C.R. Wahrer, D. W. Bell, G. Chang, S. Hegde, D. Neuberg, T. Shafman, N. J. Tarbell, et al.
Heterozygous Germline ATM Mutations Do Not Contribute to Radiation-Associated Malignancies After Hodgkin's Disease
J. Clin. Oncol., April 1, 1999; 17(4): 1259 - 1259.
[Abstract] [Full Text] [PDF]


Home page
BMJHome page
M. Lavin
Role of the ataxia-telangiectasia gene (ATM) in breast cancer
BMJ, August 22, 1998; 317(7157): 486 - 487.
[Full Text]


Home page
ScienceHome page
M. Meyn
High spontaneous intrachromosomal recombination rates in ataxia-telangiectasia
Science, May 28, 1993; 260(5112): 1327 - 1330.
[Abstract] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1988 by the American Association for Cancer Research.